AI is revolutionizing drug discovery, as exemplified by Insilico Medicine's development of a novel pill for idiopathic pulmonary fibrosis (IPF), which has shown promising results in trials. Companies like Alphabet's Isomorphic Labs and Recursion Pharmaceuticals are also utilizing AI to identify therapeutic targets and design molecules faster and more efficiently. While challenges such as data limitations remain, the integration of AI in this field holds the potential to significantly reduce costs and improve success rates in drug development.
